In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing ...

Researchers assessed whether a set dose of luspatercept could be safe in treating pediatric patients with non–transfusion dependent beta-thalassemia.

Chalice Mining Limited ( CGMLF) Discusses Gonneville Project Pre-Feasibility Study and Strategic Development Outlook December 7, 2025 7:01 PM EST ...

The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...

The combination of talquetamab-tgvs and pomalidomide achieved an 85.7% objective response rate in relapsed/refractory multiple myeloma patients. Median progression-free survival was 25.8 months, with ...

Younger age at diagnosis did not appear to affect outcomes among women with breast cancer who harbor BRCA mutations, ...

ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss.

In the phase 3 COBRA trial, the carfilzomib/lenalidomide/dexamethasone regimen shows significant improvements in PFS and ...

Vorasidenib significantly reduced tumor growth rates in IDH1/2-mutant grade 2 glioma, improving PFS and TTNI compared to ...

Aurum Resources continues to deliver strong gold results at its Napié project in Côte d’Ivoire, hitting wide, high-grade intercepts that support further resource growth.

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...